BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype.

Al-Shamsi, Humaid O; Anand, Deepa; Shroff, Rachna T; Jain, Apurva; Zuo, Mingxin; Conrad, Claudius; Vauthey, Jean-Nicolas; Javle, Milind M

Al-Shamsi, Humaid O; Anand, Deepa; Shroff, Rachna T; Jain, Apurva; Zuo, Mingxin; Conrad, Claudius; Vauthey, Jean-Nicolas; Javle, Milind M.

Afiliación

Al-Shamsi HO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anand D; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shroff RT; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jain A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zuo M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Conrad C; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Vauthey JN; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Javle MM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

J Gastrointest Oncol ; 7(4): 556-61, 2016 Aug.

Article en En | MEDLINE | ID: mdl-27563445

Palabras clave

BAP1-mutant cholangiocarcinoma; Foundation Medicine; cisplatin; gemcitabine; next-generation sequencing (NGS)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: J Gastrointest Oncol Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google